A citation-based method for searching scientific literature

Christopher P Childers, Kimberly K Childers, Melinda Maggard-Gibbons, James Macinko. J Clin Oncol 2017
Times Cited: 130







List of co-cited articles
569 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial.
Susan V Montgomery, Andrea M Barsevick, Brian L Egleston, Ruth Bingler, Karen Ruth, Suzanne M Miller, John Malick, Terrence P Cescon, Mary B Daly. Fam Cancer 2013
44
6

BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
D M Eccles, G Mitchell, A N A Monteiro, R Schmutzler, F J Couch, A B Spurdle, E B Gómez-García. Ann Oncol 2015
109
3

Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
Casey L Swanson, Amanika Kumar, Joy M Maharaj, Jennifer L Kemppainen, Brittany C Thomas, Megan R Weinhold, Kristine M Slaby, Kristin C Mara, Myra J Wick, Jamie N Bakkum-Gamez. Gynecol Oncol 2018
13
23

Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives.
Kristen Dilzell, Kerry Kingham, Kelly Ormond, Uri Ladabaum. Fam Cancer 2014
22
13

The past, present and future of service delivery in genetic counseling: Keeping up in the era of precision medicine.
Katie Stoll, Shobana Kubendran, Stephanie A Cohen. Am J Med Genet C Semin Med Genet 2018
54
5

BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.
Katherine Kolor, Zhuo Chen, Scott D Grosse, Juan L Rodriguez, Ridgely Fisk Green, W David Dotson, M Scott Bowen, Julie A Lynch, Muin J Khoury. MMWR Surveill Summ 2017
19
15

BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
Danielle S Chun, Brygida Berse, Vickie L Venne, Scott L DuVall, Kelly K Filipski, Michael J Kelley, Laurence J Meyer, Michael S Icardi, Julie A Lynch. Fam Cancer 2017
9
33


ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.
Sapna Syngal, Randall E Brand, James M Church, Francis M Giardiello, Heather L Hampel, Randall W Burt. Am J Gastroenterol 2015
624
3

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Julie Lecarpentier, Valentina Silvestri, Karoline B Kuchenbaecker, Daniel Barrowdale, Joe Dennis, Lesley McGuffog, Penny Soucy, Goska Leslie, Piera Rizzolo, Anna Sara Navazio,[...]. J Clin Oncol 2017
70
4

Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Kasmintan A Schrader, Jane Hurlburt, Steve E Kalloger, Samantha Hansford, Sean Young, David G Huntsman, C Blake Gilks, Jessica N McAlpine. Obstet Gynecol 2012
84
3

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
3

Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Jan Hauke, Judit Horvath, Eva Groß, Andrea Gehrig, Ellen Honisch, Karl Hackmann, Gunnar Schmidt, Norbert Arnold, Ulrike Faust, Christian Sutter,[...]. Cancer Med 2018
54
5

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
3

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, Alexander Gutin, Larissa A Meyer, Darl D Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn,[...]. J Clin Oncol 2010
240
3

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
Matthew B Yurgelun, Matthew H Kulke, Charles S Fuchs, Brian A Allen, Hajime Uno, Jason L Hornick, Chinedu I Ukaegbu, Lauren K Brais, Philip G McNamara, Robert J Mayer,[...]. J Clin Oncol 2017
165
3

Alternate Service Delivery Models in Cancer Genetic Counseling: A Mini-Review.
Adam Hudson Buchanan, Alanna Kulchak Rahm, Janet L Williams. Front Oncol 2016
55
5

BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer.
Jan Norum, Eli Marie Grindedal, Cecilie Heramb, Inga Karsrud, Sarah Louise Ariansen, Dag Erik Undlien, Ellen Schlichting, Lovise Mæhle. ESMO Open 2018
10
30

Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group.
Amy Taylor, Angela F Brady, Ian M Frayling, Helen Hanson, Marc Tischkowitz, Clare Turnbull, Lucy Side. J Med Genet 2018
43
6

Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO).
Min Chul Choi, Myong Cheol Lim, Dong Hoon Suh, Yong Jung Song, Tae Joong Kim, Suk Joon Chang, Jae Weon Kim. J Gynecol Oncol 2016
13
23

Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.
Jeffrey N Weitzel, Jessica Clague, Arelis Martir-Negron, Raquel Ogaz, Josef Herzog, Charité Ricker, Chelsy Jungbluth, Cheryl Cina, Paul Duncan, Gary Unzeitig,[...]. J Clin Oncol 2013
99
3

African American women's limited knowledge and experiences with genetic counseling for hereditary breast cancer.
Vanessa B Sheppard, Kristi D Graves, Juleen Christopher, Alejandra Hurtado-de-Mendoza, Costellia Talley, Karen Patricia Williams. J Genet Couns 2014
31
9

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017
3

Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer.
Lisa R Susswein, Cécile Skrzynia, Leslie A Lange, Jessica K Booker, Mark L Graham, James P Evans. J Clin Oncol 2008
42
7

What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2.
Inez Adams, Juleen Christopher, Karen Patricia Williams, Vanessa B Sheppard. J Cancer Educ 2015
23
13

Patient satisfaction with health care decisions: the satisfaction with decision scale.
M Holmes-Rovner, J Kroll, N Schmitt, D R Rovner, M L Breer, M L Rothert, G Padonu, G Talarczyk. Med Decis Making 1996
386
3

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
3

Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.
Alyssa Kne, Heather Zierhut, Shari Baldinger, Karen K Swenson, Pamela Mink, Patricia McCarthy Veach, Michaela L Tsai. J Genet Couns 2017
16
18

Germline Mutations in Predisposition Genes in Pediatric Cancer.
Jinghui Zhang, Michael F Walsh, Gang Wu, Michael N Edmonson, Tanja A Gruber, John Easton, Dale Hedges, Xiaotu Ma, Xin Zhou, Donald A Yergeau,[...]. N Engl J Med 2015
494
3

The future of clinical cancer genomics.
Kenneth Offit. Semin Oncol 2016
13
23

Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?
Susan M Domchek, Angela Bradbury, Judy E Garber, Kenneth Offit, Mark E Robson. J Clin Oncol 2013
156
3




PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
801
3

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
R Moslehi, W Chu, B Karlan, D Fishman, H Risch, A Fields, D Smotkin, Y Ben-David, J Rosenblatt, D Russo,[...]. Am J Hum Genet 2000
225
3

Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.
Melissa K Frey, Ryan M Kahn, Eloise Chapman-Davis, Francesca Tubito, Maira Pires, Paul Christos, Samantha Anderson, Semanti Mukherjee, Bailey Jordan, Stephanie V Blank,[...]. J Clin Oncol 2020
17
17

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
3

A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.
Holly LaDuca, Eric C Polley, Amal Yussuf, Lily Hoang, Stephanie Gutierrez, Steven N Hart, Siddhartha Yadav, Chunling Hu, Jie Na, David E Goldgar,[...]. Genet Med 2020
53
5

Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers.
Alicia Swink, Anju Nair, Pamela Hoof, Antoinette Matthews, Chelsey Burden, Kelly Johnson, Joanne L Blum. Proc (Bayl Univ Med Cent) 2019
10
30

Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic.
Sue V Petzel, Rachel Isaksson Vogel, Tracy Bensend, Anna Leininger, Peter A Argenta, Melissa A Geller. J Genet Couns 2013
30
10

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Ella R Thompson, Simone M Rowley, Na Li, Simone McInerny, Lisa Devereux, Michelle W Wong-Brown, Alison H Trainer, Gillian Mitchell, Rodney J Scott, Paul A James,[...]. J Clin Oncol 2016
110
3

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
B B Roa, A A Boyd, K Volcik, C S Richards. Nat Genet 1996
543
3

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
Sarah Jervis, Honglin Song, Andrew Lee, Ed Dicks, Patricia Harrington, Caroline Baynes, Ranjit Manchanda, Douglas F Easton, Ian Jacobs, Paul P D Pharoah,[...]. J Med Genet 2015
33
9

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N Grisham, Paul J Goodfellow, Elise C Kohn, Douglas A Levine, Joyce F Liu, Karen H Lu,[...]. J Clin Oncol 2020
44
6

Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.
Margaret I Liang, Deanna H Wong, Christine S Walsh, Robin Farias-Eisner, Joshua G Cohen. J Genet Couns 2018
10
30

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
338
3

Gene panel testing for inherited cancer risk.
Michael J Hall, Andrea D Forman, Robert Pilarski, Georgia Wiesner, Veda N Giri. J Natl Compr Canc Netw 2014
78
3

Breast cancer in the personal genomics era.
Rachel E Ellsworth, David J Decewicz, Craig D Shriver, Darrell L Ellsworth. Curr Genomics 2010
54
5

Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing.
Jacqueline Mersch, Nichole Brown, Sara Pirzadeh-Miller, Erin Mundt, Hannah C Cox, Krystal Brown, Melissa Aston, Lisa Esterling, Susan Manley, Theodora Ross. JAMA 2018
76
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.